Bertrand Bellier

Bertrand Bellier

Auto-generated profile, based on publicly available information

Bertrand Bellier

Immunology, Immunopathology, Immunotherapy, INSERM U959, Pitié Salpétrière Hospital, Sorbonne University, Paris, France

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GCGuillaume Churlaud
Guillaume Churlaud
FPFabien Pitoiset
Fabien Pitoiset
FJFadi Jebbawi
Fadi Jebbawi
RLRoberta Lorenzon
Roberta Lorenzon
BBBertrand Bellier
Bertrand Bellier
DKDavid Klatzmann
David Klatzmann
In addition to CD4+ regulatory T cells (Tregs), CD8+ suppressor T cells are emerging as an important subset of regulatory T cells. Diverse populations of CD8+ T cells with suppressive activities have been described. Among them, a small population of CD8+CD25+FOXP3+ T cells is found both in mice and humans. In contrast to thymic-derived CD4+CD25+FOXP3+ Tregs, their origin and their role in the pathophysiology of autoimmune diseases (AIDs) are less understood. We report here the number, phenotype, and function of CD8+ Tregs cells in mice and humans, at the steady state and in response to low-dose interleukin-2 (IL-2). CD8+ Tregs represent approximately 0.4 and 0.1% of peripheral blood T cells in healthy humans and mice, respectively. In mice, their frequencies are quite similar in lymph nodes (LNs) and the spleen, but two to threefold higher in Peyer patches and mesenteric LNs. CD8+ Tregs express low levels of CD127. CD8+ Tregs express more activation or proliferation markers such as CTLA-4, ICOS, and Ki-67 than other CD8+ T cells. In vitro, they suppress effector T cell proliferation as well as or even better than CD4+ Tregs. Owing to constitutive expression of CD25, CD8+ Tregs are 20- to 40-fold more sensitive to in vitro IL-2 stimulation than CD8+ effector T cells, but 2–4 times less than CD4+ Tregs. Nevertheless, low-dose IL-2 dramatically expands and activates CD8+ Tregs even more than CD4+ Tregs, in mice and humans. Further studies are warranted to fully appreciate the clinical relevance of CD8+ Tregs in AIDs and the efficacy of IL-2 treatment.

3 August 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PGPierre Garrone
Pierre Garrone
AFAnne-Catherine Fluckiger
Anne-Catherine Fluckiger
PMPhilippe E. Mangeot
Philippe E. Mangeot
EGEmmanuel Gauthier
Emmanuel Gauthier
PDPia Dupeyrot-Lacas
Pia Dupeyrot-Lacas
CDCharlotte Dalba
Charlotte Dalba
Virus-like particles pseudotyped with heterologous viral envelopes stimulate broadly cross-neutralizing antibodies against HCV.

16 June 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
TCTristan Courau
Tristan Courau
DNDjamel Nehar-Belaid
Djamel Nehar-Belaid
LFLaura Florez
Laura Florez
BLBéatrice Levacher
Béatrice Levacher
TVThomas Vazquez
Thomas Vazquez
DKDavid Klatzmann
David Klatzmann
Tregs imprint an early immunotolerant tumor environment that prevents effective antitumor immune responses. Using transcriptomics of tumor tissues, we identified early upregulation of VEGF and TGF-β pathways compatible with tolerance imprinting. Silencing of VEGF or TGF-β in tumor cells induced early and pleiotropic modulation of immune-related transcriptome signatures in tumor tissues. These were surprisingly similar for both silenced tumors and related to common downstream effects on Tregs. Silencing of VEGF or TGF-β resulted in dramatically delayed tumor growth, associated with decreased Tregs and myeloid-derived suppressor cells and increased effector T cell activation in tumor infiltrates. Strikingly, co-silencing of TGF-β and VEGF led to a substantial spontaneous tumor eradication rate and the combination of their respective inhibitory drugs was synergistic. VEGF and/or TGF-β silencing also restored tumor sensitivity to tumor-specific cell therapies and markedly improved the efficacy of anti–PD-1/anti–CTLA-4 treatment. Thus, TGF-β and VEGF cooperatively control the tolerant environment of tumors and are targets for improved cancer immunotherapies.

3 August 2009 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GDGuillaume Darrasse-Jeze
Guillaume Darrasse-Jeze
ABAnne-Sophie Bergot
Anne-Sophie Bergot
ADAurélie Durgeau
Aurélie Durgeau
FBFabienne Billiard
Fabienne Billiard
BSBenoît L. Salomon
Benoît L. Salomon
DKDavid Klatzmann
David Klatzmann
Early responses of Tregs and effector T cells (Teffs) to their first encounter with tumor cells have been poorly characterized. Here we have shown, in both implanted and in situ–induced mouse tumor models, that the appearance of tumor cells is immediately sensed by CD44hi memory Tregs that are specific for self antigens. The rapid response of these Tregs preceded and prevented activation of naive antitumor Teffs. The relative speed of the Treg versus the Teff response within the first 2–4 days determined the outcome of the antitumor immune response: tolerance or rejection. If antitumor memory Teffs were present at the time of tumor emergence, both Tregs and Teffs were recruited and activated with memory kinetics; however, the Tregs were unable to control the Teffs, which eradicated the tumor cells. This balance between effector and regulatory responses did not depend on the number of Tregs and Teffs, but rather on their memory status. Thus, in the natural setting, dominant tolerogenic immunosurveillance by self-specific memory Tregs protects tumors, just as it protects normal tissues. More generally, our results reveal that the timing of Treg and Teff engagement, determined by their memory status, is an important mode of regulation of immune responses.

1 March 2011 in Molecular Therapy
Verified
Journal Article
Open access
LTLea Torrieri-Dramard
Lea Torrieri-Dramard
BLBénédicte Lambrecht
Bénédicte Lambrecht
Helena Lage FerreiraHelena Lage Ferreira
Helena Lage Ferreira
TBThierry Van Den Berg
Thierry Van Den Berg
DKDavid Klatzmann
David Klatzmann
BBBertrand Bellier
Bertrand Bellier
The induction of potent virus-specific immune responses at mucosal surfaces where virus transmission occurs is a major challenge for vaccination strategies. In the case of influenza vaccination, this has been achieved only by intranasal delivery of live-attenuated vaccines that otherwise pose safety problems. Here, we demonstrate that potent mucosal and systemic immune responses, both cellular and humoral, are induced by intranasal immunization using formulated DNA. We show that formulation with the DNA carrier polyethylenimine (PEI) improved by a 1,000-fold the efficiency of gene transfer in the respiratory track following intranasal administration of luciferase-coding DNA. Using PEI formulation, intranasal vaccination with DNA-encoding hemagglutinin (HA) from influenza A H5N1 or (H1N1)2009 viruses induced high levels of HA-specific immunoglobulin A (IgA) antibodies that were detected in bronchoalveolar lavages (BALs) and the serum. No mucosal responses could be detected after parenteral or intranasal immunization with naked-DNA. Furthermore, intranasal DNA vaccination with HA from a given H5N1 virus elicited full protection against the parental strain and partial cross-protection against a distinct highly pathogenic H5N1 strain that could be improved by adding neuraminidase (NA) DNA plasmids. Our observations warrant further investigation of intranasal DNA as an effective vaccination route.

1 June 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
CCCloé Comarmond
Cloé Comarmond
MGMarlène Garrido
Marlène Garrido
SPStanislas Pol
Stanislas Pol
ADAnne-Claire Desbois
Anne-Claire Desbois
MCMyrto Costopoulos
Myrto Costopoulos
DSDavid SAADOUN
David SAADOUN